12 completed, 5 unknown, 3 recruiting, 1 active not recruiting. 5 Phase 1, 4 Phase 2, 4 Phase 4, 3 Phase 3, 2 Early Phase 1.
Follow Metyrapone: new trials by email Literature Review of Metyrapone trials Research Report on Metyrapone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-01 | 2026-09-25 |
| Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance Metyrapone And Hydrocortisone, Dextrose, insulin - Shift Work Schedule, Circadian Rhythm | Phase 4 | Recruiting | Washington State University | 48 | 2026-07-16 | 2026-09-18 |
| Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS) Metyrapone 250 mg Oral Tablets, Osilodrostat 1 MG, adrenalectomy - Mild Autonomous Cortisol Secretion (MACS) | Phase 4 | Recruiting | Laikο General Hospital, Athens | 150 | 2025-12-01 | 2025-12-05 |
| Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake Metyrapone And Hydrocortisone, Placebo - Glucocorticoids, Overweight and Obesity | Not applicable | Completed | Eleonora Seelig | 23 | 2024-09-01 | 2026-05-22 |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) Metyrapone - Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS) | Phase 2 | Active not recruiting | Mayo Clinic | 30 | 2023-12-19 | 2026-09-25 |
| The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve) Metyrapone 250 mg Oral Tablets, Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo 250 mg Tablets - Glucocorticoid Effect | Early Phase 1 | Completed | Eleonora Seelig | 24 | 2023-05-15 | 2024-08-14 |
| Effects of Metyrapone in Patients With Hypercortisolism Metyrapone Capsules - Hypercortisolism | Completed | Istituto Auxologico Italiano | 20 | 2022-04-28 | 2026-03-30 | |
| Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals Metyrapone 250 mg Oral Tablets, Placebo 250 mg Tablets, Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s - Glucocorticoid Effect | Early Phase 1 | Completed | Eleonora Seelig | 20 | 2022-02-08 | 2023-08-23 |
| Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment EMB-01 - Smoking Cessation, Tobacco Use Disorder | Phase 2 / Phase 3 | Unknown | Rose Research Center, LLC | 25 | 2021-05-19 | 2021-05-28 |
| Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Metyrapone - Depressive Disorder, Hormone Disturbance | Phase 4 | Unknown | Centre Hospitalier Rouffach | 14 | 2018-12-22 | 2020-09-09 |
| A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine EMB-001, Placebo, Cocaine IV - Cocaine Use Disorder | Phase 1 | Completed | Embera NeuroTherapeutics, Inc. | 18 | 2016-07-01 | 2017-08-01 |
| Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome metyrapone - Cushing's Syndrome | Phase 3 | Completed | HRA Pharma | 50 | 2015-04-01 | 2020-09-25 |
| Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001) metyrapone & oxazepam, Placebo - Cocaine Use Disorder, Tobacco Use Disorder | Phase 1 | Completed | Embera NeuroTherapeutics, Inc. | 24 | 2015-03-01 | 2016-07-22 |
| Cortisol and Nutritional Sympathetic Responsiveness metyrapone, placebo - Metabolic Syndrome, Obesity | Phase 4 | Unknown | Baker Heart Research Institute | 24 | 2013-02-01 | 2014-09-09 |
| Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures Metyrapone, Dexamethasone, Cortrosyn - Stress | Phase 1 | Completed | University of Michigan | 256 | 2012-10-01 | 2018-04-23 |
| Antiglucocorticoid Augmentation of antiDepressants in Depression Metyrapone, placebo - Depression | Phase 3 | Completed | Jane Barnes | 190 | 2011-02-01 | 2014-07-17 |
| A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction Metyrapone, Oxazepam, Placebo - Cocaine Dependence, Cocaine Addiction | Not applicable | Completed | Embera NeuroTherapeutics, Inc. | 45 | 2007-12-01 | 2026-09-18 |
| To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones. metyrapone, alprazolam, placebo - Depressive Disorder and Anxiety Disorders | Phase 1 | Completed | GlaxoSmithKline | 20 | 2006-10-06 | 2017-09-11 |
| Cocaine-Metyrapone Interaction Study - 1 Metyrapone - Cocaine-Related Disorders, Infusions, Intravenous | Phase 1 | Unknown | National Institute on Drug Abuse (NIDA) | 12 | 2001-11-01 | 2017-01-11 |
| Metyrapone as Additive Treatment in Major Depression Metyrapone - Major Depressive Disorder | Phase 2 | Completed | Universitätsklinikum Hamburg-Eppendorf | 63 | 1998-05-01 | 2005-08-12 |
Showing 20 of 21. Sign in to see all of them.
Cushing Syndrome (4) · Insulin Resistance (3) · ACTH Syndrome, Ectopic (2) · Adrenal Hyperplasia, Congenital (2) · Cocaine-Related Disorders (2) · Depressive Disorder (2) · Obesity (2) · Tobacco Use Disorder (2) · Anxiety Disorders (1) · Behavior, Addictive (1) · Brain Injuries (1) · Craniocerebral Trauma (1) · Depression (1) · Depressive Disorder, Major (1) · Diabetes Mellitus, Type 2 (1)
Eleonora Seelig (3) · Embera NeuroTherapeutics, Inc. (3) · Mayo Clinic (2) · Baker Heart Research Institute (1) · Centre Hospitalier Rouffach (1) · GlaxoSmithKline (1) · HRA Pharma (1) · Istituto Auxologico Italiano (1) · Jane Barnes (1) · Laikο General Hospital, Athens (1) · National Center for Research Resources (NCRR) (1) · National Institute on Drug Abuse (NIDA) (1) · Rose Research Center, LLC (1) · University of Michigan (1) · Universitätsklinikum Hamburg-Eppendorf (1)
United States (10) · Switzerland (3) · Germany (2) · Italy (2) · United Kingdom (2) · Australia (1) · Belgium (1) · France (1) · Greece (1) · Hungary (1) · Poland (1) · Romania (1) · Spain (1) · Turkey (Türkiye) (1)
Adrian Lloyd, MRCPsych (1) · Allan O House, MRCPsych (1) · Andrew M Blamire, BSc, PhD (1) · Anita S Kablinger, MD (1) · Chiodini Chiodini, Professor (1) · Debra Kelsh, MD (1) · Elaine M McColl, PhD (1) · Eleonora Seelig, PD Dr.med. (1) · Gary Connor, RN (1) · Hans P.A. Van Dongen, PhD (1) · Heinz CR Grunze, BoardCertPsy (1) · Holger Jahn, MD (1) · Ian M Anderson, FRCPsych (1) · Ian N Ferrier, MRCPsych (1)
2009 (1), 2018 (1), R01DA030932 (1), R01HL177106 (1), U01DA038879 (1)